Cipla has entered into partnership with Eli Lilly and Company (India), a 100% subsidiary of Eli Lilly and Company, a global multinational pharmaceutical leader. Under this agreement, Lilly’s Basaglar that is manufactured by Lilly will be marketed and distributed in India by Cipla. Basaglar is a once-daily insulin glargine therapy for the treatment of patients with type 1 & 2 diabetes above two years of age.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.
